ICU · GI & nutrition / infection
Severe Diarrhoea & C. difficile — Toxins, Severity & the Vancomycin/Fidaxomicin Era
Also known as C. difficile · Clostridioides difficile · Antibiotic-associated diarrhoea · Pseudomembranous colitis · Toxic megacolon · NAP1 · Ribotype 027 · Fidaxomicin · Oral vancomycin · Bezlotoxumab · Faecal microbiota transplant · FMT
The C. difficile is the key ICU cause of the severe diarrhoea — the antibiotic-associated (the clindamycin, the fluoroquinolones, the cephalosporins), the spore-forming, the toxin A and B producer, the hypervirulent NAP1 or ribotype 027. The spectrum: the diarrhoea to the pseudomembranous colitis to the toxic megacolon to the perforation. The severe (the WCC over 15, the AKI creatinine over 1.5 times, the hypoalbuminaemia, the ileus or the megacolon); the fulminant (the shock, the megacolon, the perforation). The diagnosis: the GDH plus the toxin (the two-step); the PCR detects the colonisation, not the active disease (the over-diagnosis). The treatment (IDSA 2021): the non-severe the fidaxomicin OR the oral vancomycin 125 mg QID; the severe the oral vancomycin; the FULMINANT the vancomycin 500 mg QID plus the IV metronidazole plus-or-minus the rectal vancomycin plus the surgery (the subtotal colectomy for the megacolon). The recurrence: the bezlotoxumab, the faecal microbiota transplant. The stop the antibiotics and the PPI; the soap-and-water hand hygiene (the alcohol gel does not kill the spores); the isolate.
Checked against its sources on 9 Oct 2026
Practise this topic
On this page
Study tools
Your progress
Saved on this device.
Target exams
Meet the patient
A 72-year-old man, day 14 of piperacillin-tazobactam for hospital-acquired pneumonia and on a PPI for stress-ulcer prophylaxis, is now in vasopressor-requiring shock with a white count of 38 and a lactate of 4.2. He has passed no stool for 36 hours, his abdomen is distended, and the CT shows a caecum of 11 cm with marked colonic wall thickening.[1]
The trap that catches the unwary is written into that vignette: the worst C. difficile often has no diarrhoea, because an ileus has shut down stool output while toxin-mediated injury races on. Any ICU patient with unexplained marked leucocytosis, abdominal distension and recent antibiotics is fulminant C. difficile until proven otherwise.[1]
References24ShowHide
- [1]Johnson S, Lavergne V, Skinner AM, et al. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults Clin Infect Dis, 2021.PMID 34164674
- [2]Wilcox MH, Gerding DN, Poxton IR, et al. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection N Engl J Med, 2017.PMID 28121498
- [3]Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection N Engl J Med, 2011.PMID 21288078
- [4]van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile N Engl J Med, 2013.PMID 23323867
- [5]Hvas CL, Dahl Jørgensen SM, Jørgensen SP, et al. Fecal Microbiota Transplantation Is Superior to Fidaxomicin for Treatment of Recurrent Clostridium difficile Infection Gastroenterology, 2019.PMID 30610862
- [6]Zhao Z, Wu Y, Geng X, et al. Efficacy of fidaxomicin versus vancomycin in the treatment of Clostridium difficile infection: A systematic meta-analysis Medicine (Baltimore), 2024.PMID 39121324
- [7]Juo YY, Sanaiha Y, Jabaji Z, et al. Trends in Diverting Loop Ileostomy vs Total Abdominal Colectomy as Surgical Management for Clostridium difficile Colitis JAMA Surg, 2019.PMID 31268492
- [8]Johnson S, Louie TJ, Gerding DN, et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials Clin Infect Dis, 2014.PMID 24799326
- [9]Loo VG, Brassard P, Poirier L, et al. Host and pathogen factors for Clostridium difficile infection and colonization N Engl J Med, 2011.PMID 22047560
- [10]Oshima T, Wu L, Li M, et al. Magnitude and direction of the association between Clostridium difficile infection and proton pump inhibitors in adults and pediatric patients: a systematic review and meta-analysis J Gastroenterol, 2018.PMID 28744822
- [11]Kwon JH, Olsen MA, Dubberke ER. The morbidity, mortality, and costs associated with Clostridium difficile infection Infect Dis Clin North Am, 2015.PMID 25677706
- [12]Fischer M, Vaughn BP, Peery AF, Kelly CR. AGA Clinical Practice Update on Management of Clostridioides difficile Infection in Adults: Expert Review Clin Gastroenterol Hepatol, 2026.PMID 42383946
- [13]Forrester JD, Colling KP, Diaz JJ, et al. Surgical Infection Society Guidelines for Total Abdominal Colectomy versus Diverting Loop Ileostomy with Antegrade Intra-Colonic Lavage for the Surgical Management of Severe or Fulminant, Non-Perforated Clostridioides difficile Colitis Surg Infect (Larchmt), 2022.PMID 34619068
- [14]Lamontagne F, Labbé AC, Haeck O, et al. Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain Ann Surg, 2007.PMID 17245181
- [15]Sailhamer EA, Carson K, Chang Y, et al. Fulminant Clostridium difficile colitis: patterns of care and predictors of mortality Arch Surg, 2009.PMID 19451485
- [16]Neal MD, Alverdy JC, Hall DE, et al. Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease Ann Surg, 2011.PMID 21865943
- [17]Oughton MT, Loo VG, Dendukuri N, et al. Hand hygiene with soap and water is superior to alcohol rub and antiseptic wipes for removal of Clostridium difficile Infect Control Hosp Epidemiol, 2009.PMID 19715426
- [18]Warny M, Pepin A, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe Lancet, 2005.PMID 16182895
- [19]Lyras D, O'Connor JR, Howarth PM, et al. Toxin B is essential for virulence of Clostridium difficile Nature, 2009.PMID 19252482
- [20]van Prehn J, Reigadas E, Vogelzang EH, et al. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults Clin Microbiol Infect, 2021.PMID 34678515
- [21]Guery B, Menichetti F, Anttila VJ, et al. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial Lancet Infect Dis, 2018.PMID 29273269
- [22]Cornely OA, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial Lancet Infect Dis, 2012.PMID 22321770
- [23]Crobach MJ, Planche T, Eckert C, et al. European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection. Clin Microbiol Infect, 2016.PMID 27460910
- [24]Gateau C, Couturier J, Coia J, et al. How to: diagnose infection caused by Clostridium difficile. Clin Microbiol Infect, 2018.PMID 29269092